Overview

Collaborative Risk-stratified Investigation in Teen Inpatients With Critical Illness: Anticoagulation With LMWH in Kids for ThromboProphylaxis (CRITICAL-Kids-TP)

Status:
NOT_YET_RECRUITING

Trial end date:
2030-06-30

Target enrollment:

Participant gender:

Summary

Critically ill adolescents are at greatest risk for developing hospital-acquired venous thromboembolism. To date, no phase 3 randomized controlled trials have been conducted for pharmacological thromboprophylaxis as primary venous thromboembolism prevention in children. The investigators will perform a United States definitive multicenter phase 3 randomized controlled trial of the low molecular weight heparin dalteparin as primary venous thromboembolism prophylaxis among critically ill adolescents who are classified a priori as high risk based upon the investigators validated risk prediction models.

Phase:

PHASE3

Details

Lead Sponsor:

Johns Hopkins All Children's Hospital

Collaborator:

University of California, San Diego

Treatments:

Dalteparin